An editorial and community platform for shareholders who want to understand, engage with, and dialogue constructively with the companies they own.
« We are not an activist fund. We are not trying to impose a vision. We offer common ground — that of an informed shareholder base that understands, questions, and engages. Without aggression, without complacency. »
Structured company files: thesis, catalysts, risks, calendar. Facts, not noise.
A posture of mutual engagement with management. Capcordia is common ground, not combative activism.
Long-term shareholders who share a rigorous reading of the files and prepare for general meetings.
Capcordia is built around a small number of deeply researched files.
French biotech based near Montpellier, specialised in long-acting injectable formulations through its BEPO® platform. Its thesis rests on a royalty model from partnerships with major pharma companies.
Swiss/Icelandic ophthalmology biotech listed on Nasdaq. Oculis is developing a focused pipeline of topical and neuroprotective candidates for major ophthalmic markets: diabetic macular oedema, dry eye disease, retinal neuroprotection.